Clinical trial
EMPOX - A Randomised, Double-blinded, Placebo Controlled Study That Evaluates the Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
NCT02890745 is registered in ClinicalTrials.gov with Henrik Enghusen Poulsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- EMPOX - A Randomised, Double-blinded, Placebo Controlled Study That Evaluates the Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
- Lead sponsor
- Henrik Enghusen Poulsen
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- January 22, 2020
- Enrollment
- 31 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.